Enlicitide Meaningfully Lowers LDL-C at 24 Weeks in Patients At Risk for ASCVD Events

“There is the hope that this can be more deployable to a broader patient population, as far as an option that can fit the scheme of how patients usually take their maintenance medications,” Joseph Saseen, PharmD, BCPS, BCACP, CLS, Professor and Associate Dean for Clinical Affairs, said in an interview with Pharmacy Times.